Reliability and validity of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire impact scales
The ATTR-QOL is a reliable and valid measure of impacts meaningful to patients with ATTR amyloidosis. This study resulted in updates to the ATTR-QOL for item reduction and the development of a scoring algorithm. Ongoing studies are collecting data to evaluate the symptom scales of the ATTR-QOL.
Authors
- Kristen McCausland (ORCID: https://orcid.org/0000-0003-4727-1046)
- Kristen Hsu (ORCID: https://orcid.org/0000-0003-2106-3652)
- Jakob Bue Bjørner (ORCID: https://orcid.org/0000-0001-7033-8224)
- Isabelle Lousada (ORCID: https://orcid.org/0000-0002-3506-0359)
- Andrew Lovley (ORCID: https://orcid.org/0000-0001-9118-0673)
- Sabrina Rebello (ORCID: https://orcid.org/0000-0002-0201-4030)
- Kaitlin LaGasse (ORCID: https://orcid.org/0000-0001-9772-5822)
- Michelle K. White (ORCID: https://orcid.org/0000-0003-2450-7693)
Institutions
- IQVIA (United Kingdom) (GB)
- Amyloidosis Foundation (US)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1186/s41687-025-00880-7
- Citations
- 3
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Pfizer
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- Prothena